“…At week 24, those who had a clinical response continued the maintenance period of 200 mg SC mirikizumab (Sandborn et al, 2020a). Endpoints included clinical remission (Mayo rectal bleeding 0, 0 or 1 with a 1 point decrease from baseline), clinical response, endoscopic remission (Mayo endoscopic subscore 0), or endoscopic improvement (endoscopic subscore of 0 or 1) at weeks 24 or 52 (Sandborn et al, 2020a). In the 12 weeks extension of the mirikizumab 600 mg dose and 1,000 mg mirikizumab dose, 50 and 43.8%, respectively, achieved clinical response and 15 and 9.4%, respectively, achieved clinical remission (Sandborn et al, 2020a).…”